key: cord-0866874-lqedrgc7
authors: Srivastava, Kamna; Singh, Mohan Kumar
title: Drug repurposing in COVID-19: A review with past, present and future
date: 2021-08-26
journal: Metabol Open
DOI: 10.1016/j.metop.2021.100121
sha: b84396ea5f279aac755d63247973ae99cfaf4543
doc_id: 866874
cord_uid: lqedrgc7

The coronavirus SARS-CoV-2 which causes the COVID-19 disease is a global public health emergency. Coronavirus are single-stranded positive-sense RNA viruses and their genome size is approximately 30 kb, which encodes some important structural proteins. The interaction between viral Spike protein and ACE2 on the host cell surface is of significant interest since it initiates the infection process. This review will focus on the effectiveness of reuse of currently used drugs against COVID-19, including clinical trials, molecular docking, and computational modelling approach. METHODS: A systematic search in Pubmed, MEDLINE, EMBASE was conducted from from January 2020 to July 2021. Applying computational, clinical and experimental approaches, numerous drugs such as remdesivir, favipiravir, ribavirin, lopinavir, ritonavir, tocilizumab have been repurposed and have shown promising protection against SARS-CoV2 both in vitro and in clinical conditions. Although there is only one repurposed drug approved by the U.S. Food and Drug Administration (FDA) to treat coronavirus disease 2019 (COVID-19), i.e, Remdesivir. However, the FDA withdrew the authorization of the drugs Hydroxychloroquine and chloroquine,that are not effective for COVID-19 and can also cause serious heart problems. Molecular coupling would be the ideal technique to identify such therapeutic agents against COVID19.

The COVID-19 pandemic situation is constantly evolving worldwide. Globally, as of 14 Outbreaks of COVID-19, pose challenges for therapeutic / drug treatments in the clinical setting with very little time available for novel drug discovery. Furthermore, development of a vaccine for any disease, including COVID-19, is time taking process and in accelerated mode also it would take 18-20 months to introduce it as a ready-to-use product. Therefore, there is a need for an utmost search for effective therapeutic agents to treat COVID-19 2 . Drug reuse, is also known as drug repurposing, defined as the search for new indications for existing drugs.

It is believed that 75% of known drugs could be repurposed for various diseases. The advantage of drug repurposing is that we have a range of pre-clinical (pharmacological, toxicological, etc), and clinical efficacy and safety data already available, as the candidate drug has already undergone through the prior drug development.

The investigator reviewed the various. Literature search was performed in WHO reports, PubMed, Scopus, Science Direct, Nature, JAMA, BMJ and THE LANCET journals using following terms: repurposing of drugs, repurposing of drugs in COVID, COVID-19 and Dug and vaccines in coronaviruses to find articles published from January 2020 to June 2021. Some of the information pertaining to India is taken from the Ministry of Health, Government of India. No language limits or study design filters were applied. Drugs not related with coronaviruses, directly or indirectly, were excluded from the studies. J o u r n a l P r e -p r o o f DISCUSSIONS In cases such as the current global pandemic, where the medical scenario is unexpected and the need for treatment is high, drug repurposing presents a convenient alternative in the search for effective therapeutic agents. As the approach uses compounds with known biochemical and physiologic effects, clinical testing can begin with Phase III or IV studies, potentially offering cost and time savings. In comparison to novel drug development, drug repurposing could be an economical medical treatments for COVID-19.

SARS-CoV2 replication is directly dependent on the enzyme RNA-dependent RNA polymerase (RDRP). Interestingly, the potential protease and polymerase targets for SARS-CoV2 and SARS CoV are highly conserved with an overall identity of 96% and 97%. Hence, these blockers developed against SARS can act as good therapeutic candidates for binding protease or polymerase sites against SARS-CoV2 4 .

Use of remdesivir in SARS-CoV2 infection, is considered to be a possible candidate drug for reuse against COVID-19. remdesivir is a nucleotide analog (adenosine), which is fused with the replicating genome of the virus and forms its triphosphate form which further compete with adenosine triphosphate (ATP) to act as a substrate for RDRP. Remdesivir adds three more nucleotides before terminating the growing RNA strand. The three additional nucleotides can protect the 3′-5 ′ viral exonuclease clearance inhibitor activity 5 . Ineffective against Ebola, Remdesivir has shown its efficacy against SARS-CoV2 in preclinical as well as clinical cases. 6 Several clinical trials have been conducted to test efficacy of remdesivir in COVID-19.

However, the results were conflicting. A study treated a cohort of 53 patients with severe COVID-19 with compassionate use of remdesivir for 10 days, 200 mg intravenously on day 1 and 100 mg for the next 9 day. The results show that after the first dose of remdesivir, 68% of patients showed clinical improvements in oxygen support 7 . Another study in Italy administered remdesivir for compassionate use to 10 days to a cohort of 35 severe COVID -19 patients in both the ICU and infectious disease ward, and the results indicate that remdesivir benefits patients outside the ICU 8 . The FDA has approved remdesivir (Veklury) to treat COVID-19 in J o u r n a l P r e -p r o o f adults and children who are age 12 and older. Remdesivir may be prescribed for people who are hospitalized with COVID-19. It's given through a needle in the skin (intravenously).

Favipiravir has similar mechanism of incorporation of ATP and GTP into RdRp, however it is not as effective as remdesivir 9 . In an open-label, non-randomized controlled study, the effects of favipiravir and ritonavir-lopinavir on Treatment with SARS-CoV-2 was compared. The favipiravir group showed a significantly shorter virus spread time, better chest images and fewer adverse reactions 10 .

Ribavirin used for the treatment of hepatitis C. The mechanism of ribavirin is similar to that of favipiravir [9] . A phase 2, randomized, open-label study evaluated the Efficacy of a combination of IFN-β-1b, lopinavir / ritonavir and ribavirin in the treatment of SARS-CoV-2 infected patients. The study demonstrated that triple therapy was superior to using lopinavir / ritonavir alone in the treatment of patients with mild or moderate SARS-CoV-2 infection 11 .

Protease Inhibitors used in HIV-1 therapy have been shown to be effective in SARS-CoV. Insilico and in-vitro approaches were used to validate the inhibition of SARS-CoV2 protease from HIV-1 protease inhibitors 12 . Examples are saquinavir, amprenavir, indinavir, nelfnavir, ritonavir and lopinavir, few of them are being repurposed against SARS-CoV2.

Since CoV replication and gene expression processes require the proteolytic processing of polypeptides into non-structural proteins, it is suggested to use protease inhibitors to block these processes. Examples of this category are darunavir and ritonavir -lopinavir. Ritonavirlopinavir combination is used as AIDS drug that inhibits the HIV protease. A retrospective study including 120 patients shows that early administration of ritonavir -lopinavir could reduce the time to onset of the virus detachment in SARS-COV-2 13 . A controlled study involving 47 patients with COVID-19 infection indicated that a combination of ritonavirlopinavir and adjuvant drugs significantly reduced the number of days for clearance compared to adjuvant drugs alone 14 . In a retrospective cohort study, 50 patients were split into ritonavir J o u r n a l P r e -p r o o f lopinavir group and arbidol group and compared to the ritonavir-lopinavir group, viral clearance is faster in patients in the arbidol group 15 .

Darunavir is also a protease inhibitor originally used for HIV. Worsening of respiratory function caused by SARS was reported by Riva et al 16 Hydroxychloroquine is the hydroxylated form of chloroquine and therefore they share similar antiviral mechanisms. Some studies have found hydroxychloroquine to be effective for mild treatment with COVID-19 20 . In a study with a cohort of 80 mildly infected patients showed that combination therapy with hydroxychloroquine and azithromycin can improve the situation of the infected patients 21 . However, another study claimed it did not see clinical improvement when the same drugs and doses were used to treat 11 severely COVID -19 infected patients 22 .

Another recent observational study of 181 SARS -CoV -2 patients who need oxygen, but not intensive care, does not support the efficacy of hydroxychloroquine 23 . The FDA recently raised the issue of safety concerns caused by chloroquine and hydroxychloroquine, including severe J o u r n a l P r e -p r o o f heart rhythm problems, blood and lymphatic system disorders, kidney damage and liver problems, and has warned against the use of these drugs outside the hospital setting.

Arbidol, is a powerful broad-spectrum antiviral agent against a broad range of enclosed and non-enveloped viruses. Arbidol and arbidol mesylate have been reported to act directly on viral replication of SARS-CoV at an early stage in vitro 24 . Arbidol's antiviral mechanism against influenza A and B involves inhibition of viral fusion by hindering the hemagglutinin membrane fusion mechanism, thus blocking the entry of the virus into the cell 25 . Treating COVID-19 patients with arbidol leads to a reduction in mortality rate and an increase in recovery rate 26 .

Statins, lipid-lowering drugs, have shown immunomodulatory properties to prevent acute lung injury in various experimental and clinical conditions, therefore, it can be used as a repurposed drug for COVID-19. The spike proteins of the virus adhere to the cell surface of ACE2 expressed in the epithelial cells of the oral mucosa, lungs, intestines, blood vessels and kidneys.

ACE2 activity has been shown to be upregulated with the use of atorvastatin 27 . Statins, which are immunomodulators, have been hypothesized to act against MERS coronaviruses 28 .

Cytokine storm is a crucial factor leading to acute respiratory distress syndrome and multiorgan failure which would suddenly aggravate the disease and eventually lead to death. Therefore, cytokine storm inhibition is an important step in the treatment of COVID-19. Drugs in this category include interleukin 6 (IL-6) inhibitors (tocilizumab) and CD24Fc 29 .

Tocilizumab, a drug used against rheumatoid arthritis and cytokine release syndrome / systemic inflammatory response syndrome 30 Dexamethasone is the first-line treatment for immune-related complications. The metabolic side effects of dexamethasone include a slight increase in blood glucose level, ocular hypertension and cataracts, neuropsychological side effects such as changes in mood and behavior, and osteoporosis 33 mainly associated with long-term high doses. WHO has added dexamethasone to COVID 19 treatment guidelines 34 .

Nitazoxanide is a broad-spectrum anthelmintic and antiviral prodrug that is metabolized to an active compound tizoxanide. It had shown inhibitory potential against low concentration SARS-CoV2 in Vero E6 cells 35 .

Ivermectin, a broad-spectrum anti-parasitic agent has also been shown to be effective against some viral infections. Recently, this drug was studied against SARS-CoV2. In March 2021, the FDA issued a statement that ivermectin should not be used to treat or prevent COVID-19. There are risks associated with using ivermectin, even for approved uses. For example, ivermectin can interact with other medications, such as blood thinners, and increase the risk of bleeding.

The NIH currently does not have enough data to recommend for or against using ivermectin for COVID-19 36 . This has now been approved for emergency use in Cuba, partly on the basis of Indian data and J o u r n a l P r e -p r o o f approval, according to Cuban media. DCGI has approved itolizumab for treating moderate to severe acute respiratory distress in people with COVID-19 48 . Molecular coupling would be the central technique to identify likely therapeutic agents against COVID19 patients. In future, these drugs could be the potential drug therapy against this deadly disease.

Coronavirus disease

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

Coronavirus genomics and bioinformatics analysis

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering

Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach

Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection

Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Darunavir does not prevent SARS-CoV-2 infection in HIV patients

Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Treating COVID-19 with Chloroquine

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy

Clinical trials on drug repositioning for COVID-19 treatment. Revista panamericana de salud publica

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection

Statins may decrease the Fatality Rate of MERS Infection

The role of oseltamivir in the treatment and prevention of influenza in children

Tocilizumab (Actemra)

Tocilizumab treatment in COVID-19: A single center experience

Dexamethasone: chondroprotective corticosteroid or catabolic killer?

Coronavirus disease (COVID-19): Dexamethasone

Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening

Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes

Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins. ChemRxiv : the preprint server for chemistry

COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?

Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19

Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2

Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study

Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug

Scientists criticize use of unproven COVID drugs in India

No any funding was utilized for the preparation of this Review by the authors.

Conceptualization, Resources, formal analysis, writing, review and editing KS; Resources, writing, draft preparation, MKS;All authors have read and agreed to the publishing of the manuscript.

The authors declare no conflict of interest.

The authors have declared that no competing interest exists.J o u r n a l P r e -p r o o f